Lisinopril
ACE inhibitor for hypertension and heart failure. Not metabolized; excreted unchanged in urine. Effective half-life ~12 hours supports once-daily dosing.
Projected serum levels — 10 mg, once daily
Maintenance schedule: 10 mg once daily (oral).
Loading schedule: 14.1 mg on day 1, then 10 mg once daily — reaching therapeutic levels sooner.
Modeled steady state after ~2 days: peak ≈ 2.5 mg, trough ≈ 0.99 mg body load. Population-based estimate over 15 days for a 10 mg dose at a 70 kg reference body mass — the interactive app scales curves to your doses, timing, and body mass.
Key facts
- Category
- ACE Inhibitor
- Route modeled
- Oral
- Model confidence
- inferred
- Half-life
- 12 h
- Common dose
- 10 mg
- Suggested maximum
- 40 mg/day
- Reference dose range
- 5–40 mg (single dose)
- Suggested cadence
- once daily
- Validated against
- 20 mg oral — Cmax 0.070 mg/L at 6 h
Documented interactions
-
warning
Combined OC (Drospirenone / Ethinyl Estradiol) + Lisinopril
Both drospirenone and ACE inhibitors raise potassium. Combined use increases hyperkalemia risk.
-
warning
Potassium (Citrate) + Lisinopril
ACE inhibitors reduce potassium excretion. Supplementing potassium on top risks dangerous hyperkalemia.
-
warning
Spironolactone (Anti-Androgen) + Lisinopril
Both spironolactone and ACE inhibitors raise potassium. Combined use requires potassium monitoring.
-
watch
Enalapril (Vasotec) + Lisinopril
Enalapril (Vasotec) and Lisinopril both push the ace in the same direction.
-
watch
Enalaprilat + Lisinopril
Enalaprilat and Lisinopril both push the ace in the same direction.
-
watch
Garlic Extract (Allium sativum) + Lisinopril
Garlic Extract (Allium sativum) and Lisinopril both push the ace in the same direction.
Serum checks 8 modeled interaction pairings for lisinopril across your whole stack — absorption conflicts, enzyme inhibition, and nutrient depletion included.
Research behind this entry
-
Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients (HOPE study)
Landmark HOPE trial demonstrated ACE inhibitors reduce cardiovascular events by 22%, stroke by 32%, and cardiovascular death by 26% in high-risk patients.
-
Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic (ALLHAT)
Largest hypertension trial ever (42,418 patients) found lisinopril was as effective as chlorthalidone for preventing fatal coronary heart disease, with similar outcomes across groups.
-
Assessment of Treatment with Lisinopril and Survival (ATLAS): a randomised trial of high vs low doses in patients with heart failure
RCT of 3,164 heart failure patients found high-dose lisinopril (32.5-35 mg) reduced hospitalizations by 12% compared to low-dose (2.5-5 mg), supporting higher dose targets.
3 published studies referenced in the app, each with a plain-language summary.